Skip to search formSkip to main contentSkip to account menu

OPC-6535

Known as: OPC 6535, OPC6535 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

tetomilast

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
S1745 Anti-Inflammatory Effects of Opc-6535; PDE4 May Be a New Therapeutic Target in Inflammatory Bowel Disease
2006
2006
The Effect of Tetomilast (OPC-6535) on Cultured Human Vascular Endothelial Cells: 1077
2006
2006
Tetomilast (OPC-6535): A Novel Inhibitor of Human CD4 T Cell Proliferation and Interferon-γ Release
2006
2006
Once-Daily, Oral Tetomilast (OPC-6535) in a Rat Model of Colitis: Comparative Study on Prevention and Treatment Versus 5-ASA
2006
2006
Tetomilast (OPC-6535) Protects Against Reactive Oxygen Species-Induced Cell Injury Independent of Phoshodiesterase Type 4 Inhibition: 1076
2004
2004
ONCE-DAILY, ORAL OPC-6535 IN THE TREATMENT OF ACTIVE ULCERATIVE COLITIS: 823
2003
2003
Effects of OPC-6535 on lipopolysaccharide-induced acute liver injury in the rat: involvement of superoxide and tumor necrosis factor-alpha from hepatic macrophages.
Highly Cited
2001
Highly Cited
2001
OPC-compounds prevent oxidant-induced carbonylation and depolymerization of the F-actin cytoskeleton and intestinal barrier hyperpermeability.
2000
2000
Protective effect of OPC-6535, a superoxide anion production inhibitor, on liver grafts subjected to warm ischemia during porcine liver transplantation.
1997
1997
OPC-6535, a superoxide anion production inhibitor, attenuates acute lung injury.
A large body of evidence has demonstrated that inhibition of the neutrophil's oxidant burst attenuates sepsis-induced acute lung… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)